Larvol Delta - FDA-Approves-Coherus-CIMERLI-ranibizumabeqrn-as-the-First-and-Only-Interchangeable-Biosimilar-to-Lucentis-for-All-Five-Indications-with-12-Months-of-Interchangeability-Exclusivity

Yusimry (adalimumab-aqvh) - Coherus Biosci

Cimerli (ranibizumab biosimilar) - Amneal, Formycon, Coherus Biosci, Teva

https://www.globenewswire.com/news-release/2022/08/02/2490955/0/en/FDA-Approves-Coherus-CIMERLI-ranibizumab-eqrn-as-the-First-and-Only-Interchangeable-Biosimilar-to-Lucentis-for-All-Five-Indications-with-12-Months-of-Interchangeability-Exclusivity.html

Aug 2, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next